North America Companion Diagnostics for Oncology Market Size, Share, Trends and Forecasts 2032

Key Findings

• The North America Companion Diagnostics for Oncology Market is expanding rapidly due to growth in precision oncology and targeted cancer therapies.
• Rising use of biomarker-driven treatment selection is increasing demand for companion diagnostic tests.
• Regulatory co-approval of drugs and diagnostics is strengthening test adoption pathways.
• Expansion of molecular profiling and genomic testing is accelerating kit utilization.
• Pharmaceutical–diagnostic company partnerships are reshaping development pipelines.
• Next-generation sequencing panels are complementing single-biomarker tests.
• Reimbursement variability remains a constraint in some oncology segments.
• Clinical guidelines increasingly mandate biomarker testing before therapy selection.

North America Companion Diagnostics for Oncology Market Size and Forecast

The North America Companion Diagnostics for Oncology Market is projected to grow from USD 6.3 billion in 2025 to USD 14.8 billion by 2032, registering a CAGR of 13.0% during the forecast period. Growth is driven by increasing approvals of targeted oncology drugs that require mandatory biomarker testing prior to treatment. Expansion of precision medicine programs and molecular tumor profiling is increasing test volumes.

Rising cancer incidence and broader access to genomic testing are strengthening demand. Co-development models between pharmaceutical and diagnostic companies are accelerating product launches. Technology advances in PCR, IHC, and NGS-based assays are improving test performance and scalability. The market is expected to grow strongly across North America through 2032.

Introduction

Companion diagnostics for oncology are specialized tests used to identify specific biomarkers that determine whether a patient is likely to benefit from a particular cancer therapy. These diagnostics guide treatment decisions by matching patients to targeted drugs or immunotherapies. In North America, companion diagnostics are increasingly integrated into oncology care pathways across major cancer types.

Tests are commonly based on molecular, genetic, or protein-expression markers. They are used alongside therapies targeting mutations, receptors, or pathway alterations. Companion diagnostics improve treatment effectiveness and reduce unnecessary drug exposure. As precision oncology advances, these diagnostics are becoming a standard component of cancer care.

Future Outlook

By 2032, the companion diagnostics for oncology market in North America will be deeply integrated into routine cancer management and drug approval pathways. Most new targeted oncology drugs will launch with associated diagnostic requirements. Multiplex and comprehensive genomic profiling panels will complement single-marker tests. AI-supported interpretation tools will accelerate clinical decision-making.

Liquid biopsy–based companion diagnostics will gain wider clinical acceptance. Regulatory frameworks will further align drug and diagnostic approvals. Overall, the market will evolve toward broader biomarker coverage, faster turnaround, and tighter therapy–diagnostic coupling.

North America Companion Diagnostics for Oncology Market Trends

• Expansion of Precision Oncology and Targeted Therapy Use
  Precision oncology adoption is rising across North America as more cancer treatments target specific molecular pathways. Targeted drugs require biomarker confirmation before prescription. Clinicians increasingly rely on diagnostic-guided therapy selection. Treatment protocols are being rewritten around molecular status rather than tumor location alone. This increases routine biomarker testing volumes. Precision-driven care models are embedding companion diagnostics into oncology workflows. This trend is the strongest structural driver of market expansion.

• Growth of Regulatory Co-Development and Co-Approval Models
  Drug and diagnostic co-development is becoming standard practice in oncology innovation across North America. Pharmaceutical firms partner with diagnostic companies early in clinical development. Companion tests are validated alongside therapy trials. Regulatory agencies increasingly review drugs and diagnostics together. This reduces time-to-market alignment risk. Co-approval strengthens mandatory test adoption. This trend is tightening integration between therapeutics and diagnostics.

• Rising Use of Next-Generation Sequencing Panels
  NGS-based panels are increasingly used alongside or instead of single-marker tests in North America. Comprehensive genomic profiling detects multiple actionable mutations in one run. This improves efficiency and tissue utilization. Oncologists prefer broader panels for complex cases. Panel-based approaches identify therapy eligibility across multiple drugs. NGS workflow standardization is improving reproducibility. This trend is expanding the scope of companion diagnostics.

• Increasing Adoption of Liquid Biopsy Companion Tests
  Liquid biopsy testing is gaining traction in North America as a less invasive biomarker detection method. Blood-based assays detect tumor DNA and mutation signatures. These tests are useful when tissue samples are limited. Monitoring treatment response through liquid biopsy is increasing. Technology sensitivity is improving steadily. This trend supports repeat and longitudinal testing models.

• Integration of Digital Pathology and AI in Biomarker Testing
  Digital pathology and AI tools are increasingly used in oncology companion diagnostics. Image analysis improves biomarker scoring consistency. AI-assisted interpretation reduces variability. Workflow automation speeds reporting. Labs in North America are investing in digital diagnostic platforms. Decision support improves clinical confidence. This trend enhances diagnostic accuracy and scalability.

Market Growth Drivers

• Rising Approvals of Targeted Oncology Drugs
  Targeted oncology drug approvals are increasing steadily. Many new therapies require companion diagnostics. Drug labels often mandate biomarker testing. Therapy eligibility depends on test results. Pharmaceutical pipelines are rich in targeted agents. This directly drives diagnostic kit demand.

• Growing Global Cancer Burden and Testing Volumes
  Cancer incidence is rising across North America. Higher patient volumes increase diagnostic testing. More patients undergo molecular profiling. Earlier and repeated testing is becoming common. Screening and staging protocols include biomarker tests. Disease burden growth drives market expansion.

• Clinical Guidelines Mandating Biomarker Testing
  Oncology guidelines increasingly require biomarker testing before therapy selection. Professional societies update protocols frequently. Testing becomes standard of care. Compliance drives routine kit usage. Hospitals adopt guideline-based workflows. Guideline alignment is a major driver.

• Pharma–Diagnostics Partnerships and Funding Support
  Partnerships between drug and diagnostic companies are expanding. Joint funding supports assay development. Clinical trials include diagnostic validation arms. Shared commercialization strategies improve reach. Collaboration reduces development risk. Partnership growth accelerates innovation.

• Improved Test Accuracy and Turnaround Time
  Diagnostic technologies are becoming faster and more accurate. Improved sensitivity reduces false negatives. Automation reduces manual error. Faster turnaround supports treatment timelines. Lab efficiency improves clinician adoption. Performance gains drive demand.

Challenges in the Market

• High Test Costs and Reimbursement Gaps
  Companion diagnostic tests can be expensive in North America. Reimbursement policies vary widely. Coverage delays reduce utilization. Hospitals face budget pressure. Patients may face out-of-pocket costs. Cost barriers slow adoption in some settings.

• Complex Regulatory and Validation Requirements
  Companion diagnostics require extensive clinical validation. Regulatory approval processes are demanding. Evidence requirements are high. Development timelines are long. Cross-border regulatory variation adds complexity. Compliance burden is significant.

• Sample Quality and Tissue Availability Constraints
  Tissue biopsy samples are sometimes limited or degraded. Insufficient material affects test accuracy. Repeat biopsy is not always feasible. Pre-analytical variability impacts results. Labs must manage strict sample protocols. Sample constraints remain a challenge.

• Rapid Biomarker Evolution and Obsolescence Risk
  Biomarker science evolves quickly in oncology. Tests can become outdated as new targets emerge. Assay redesign is frequently required. Inventory and platform risk increases. Labs must continually upgrade capabilities. Obsolescence risk affects investment planning.

• Laboratory Infrastructure and Expertise Limitations
  Advanced companion diagnostics require specialized labs and staff. Not all centers in North America have required capability. Training needs are high. Equipment investment is significant. Skill gaps slow rollout. Capacity constraints limit reach.

North America Companion Diagnostics for Oncology Market Segmentation

By Technology

• PCR-Based Companion Diagnostics

• Immunohistochemistry (IHC) Tests

• In Situ Hybridization (ISH) Tests

• Next-Generation Sequencing (NGS) Tests

• Liquid Biopsy Assays

By Cancer Type

• Lung Cancer

• Breast Cancer

• Colorectal Cancer

• Melanoma

• Hematologic Cancers

• Others

By Biomarker Type

• Genetic Mutations

• Protein Expression Markers

• Gene Amplifications

• Others

By End-User

• Hospitals

• Oncology Specialty Clinics

• Diagnostic Laboratories

Leading Key Players

• Roche Diagnostics

• Agilent Technologies (Dako)

• Thermo Fisher Scientific

• QIAGEN

• Illumina, Inc.

• bioMérieux

• Abbott Molecular

• Danaher Corporation

Recent Developments

• Roche Diagnostics expanded oncology companion diagnostic portfolios aligned with targeted therapy launches in North America.

• Agilent Technologies advanced IHC and ISH companion diagnostic assays for solid tumor profiling.

• QIAGEN strengthened PCR and NGS-based companion diagnostic workflows for precision oncology.

• Thermo Fisher Scientific expanded NGS companion diagnostic kits and clinical sequencing solutions.

• Illumina, Inc. supported broader oncology panel adoption through upgraded sequencing platforms.

This Market Report Will Answer the Following Questions

1. What is the projected market size and growth rate of the North America Companion Diagnostics for Oncology Market by 2032?

2. Which technologies and cancer types drive the highest companion diagnostic demand in North America?

3. How are precision oncology and targeted drug approvals shaping testing volumes?

4. What challenges affect cost, regulation, and laboratory readiness?

5. Who are the key players leading innovation and partnerships in oncology companion diagnostics?